GLP-1R Actions on Muscle and the Skeleton

NCT07154719 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how a medication called GLP-1 receptor agonist affects muscle and bone health in adults with obesity or conditions like sarcopenic obesity and osteoporosis over a 6-month period.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 50 people Planned (estimated).

Who can join Ages 18–50 · all sexes

Timeline Started 2025-10 · est. completion 2026-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07154719 ↗

Description as written by the study sponsor.

The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

Treatments tested

Tirzepatide Drug

GLP-1 based treatment for obesity
Lifestyle toolkit Behavioral

2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.

Main thing measured	Changes in fat free mass (FFM) using DXA imaging. FFM equals all body composition that is not fat mass. This includes bone, skeletal muscle, organs, water and all connective tissues. The unit of measurement is in kilograms (kg) at baseline, 3 and 6 mo.
Sponsor	Pennington Biomedical Research Center
Conditions studied	Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07154719 ↗